Clinical Methods Core

临床方法核心

基本信息

批准号：
8470142
负责人：
THOMAS Richard KOSTEN
金额：
$ 32万
依托单位：
BAYLOR COLLEGE OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至 2015-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8470142
关键词：
Accident and Emergency department Acute Adenosine Antibodies Behavioral Research Biology Brain Cerebrum China Chinese People Chronic Clinical Clinical Pharmacology Clinical Trials Cocaine Cocaine Abuse Cocaine Dependence Collaborations Communities Complement Consultations Controlled Clinical Trials Core Facility DNA Data Collection Defect Development Disease Disulfiram Dopamine Dopamine-beta-monooxygenase Drug Addiction Drug Costs Drug abuse Education Educational Activities Evaluation FDA approved Faculty Functional Magnetic Resonance Imaging GABA transporter Generations Genetic Genetic Polymorphism Household Human Human Genetics Individual Institutes Interdisciplinary Study International Justice Knowledge Laboratories Laboratory Study Lead Life Magnetic Resonance Imaging Medicine Mentors Methamphetamine Methamphetamine dependence Methodology Methods Molecular Biology Molecular Genetics Narcotic Antagonists Neurotransmitters New Agents Nicotine Norepinephrine North America Opiates Outcome Outpatients Participant Pathway interactions Patients Perfusion Pharmaceutical Preparations Pharmacogenetics Pharmacotherapy Phase Prazosin Psychostimulant dependence Public Health Publications Relapse Relative (related person)Research Research Methodology Research Personnel Research Project Grants Safety Sampling Signal Transduction Students Subgroup Substance abuse problem Surveys Technology Transfer Testing Training Treatment Cost United States United States Substance Abuse and Mental Health Services Administration Vaccines Vasodilator Agents Visit Withdrawal base behavioral pharmacology carvedilol cocaethylene dopamine system dopamine transporter drug abuse chemotherapy endophenotype genetic selection genome wide association study improved inhibitor/antagonist innovation member nepicastat neuroimaging neurotransmission new technology noradrenergic novel prevent programs receptor research study response single photon emission computed tomography stimulant abuse treatment response

项目摘要

This Medications Development Center (MDC) for cocaine pharmacotherapy renewal has evaluated over 25 new medications, introduced many new technologies (fMRI, pharma MRI, SPECT, genetics), and facilitated multidisciplinary collaborations among clinical pharmacology, laboratory medicine, neuroimaging, and molecular genetics. We have 78 publications in the past 4 years, covering cocaine genetics (GABA transporter) to vaccines and opiate and nicotine research collaborations with the Chinese National Institute on Drug Dependence. In our continuation we will focus on medication development by modulating norepinephrine (NE) and dopamine (DA) and propose six Specific Aims 1. To conduct human laboratory cocaine- and methamphetamine (MA)-adminlstration studies with 4 new agents for safety and efficacy: RTI-336 (DA transporter blocker), SY117 (adenosine 2a inhibitor to increase DA activity), and two novel agents, YPK10A and JD-Tic (kappa opiate antagonist) (Proj 1). 2. To conduct two clinical trials of agents modulating NE activity through alpha 1-NE blockade (prazosin and carvedilol) or NE reduction by inhibiting dopamine beta hydroxylase (Proj 2 & 3). 3. To test for NE genetic matching of patients to the 3 medications in our two clinical trials. 4. To continue pilot research focused on human genetics for matching new NE and other agents to effective cocaine & MA pharmacotherapies. 5. To attract and train new drug abuse pharmacotherapy investigators through our Center's Core facilities and projects. 6. To disseminate our findings through education and international collaborations

该药物开发中心（MDC）可卡因药物疗法更新已评估超过25 新药物引入了许多新技术（fMRI，Pharma MRI，SPECT，遗传学），并促进了临床药理学，实验室医学，神经影像学和分子遗传学。在过去的4年中，我们有78个出版物，涵盖可卡因遗传学（GABA 转运蛋白）与中国国家研究所的疫苗，阿片类和尼古丁研究合作关于药物依赖。在我们的延续中，我们将通过调节来关注药物开发去甲肾上腺素（NE）和多巴胺（DA），提出了六个特定目的 1。进行人类实验室可卡因和甲基苯丙胺（MA） - 阿德米尔斯特林研究安全性和功效的代理：RTI-336（DA转运蛋白阻滞剂），SY117（腺苷2A抑制剂增加 DA活动）和两种新型药物YPK10A和JD-TIC（Kappa Opiate拮抗剂）（ProJ 1）。 2。进行两项通过Alpha 1-NE封锁调节NE活性的药物的临床试验（Prazosin 通过抑制多巴胺β羟化酶（PROJ 2和3），Carvedilol）或NE还原。 3。在我们的两项临床试验中测试患者与3种药物的NE遗传匹配。 4。继续进行试点研究，重点是人类遗传学，以使新的NE和其他代理与有效的可卡因和MA药物治疗。 5。通过我们中心的核心吸引和培训新药滥用药物治疗调查员设施和项目。 6。通过教育和国际合作传播我们的发现